Pune, India, 2023 /Market Research Future (MRFR) has published a cooked research report on the “Global Viscosupplementation Market” that contains information from 2023 to 2032. 

Viscosupplementation Market Highlights

Global Viscosupplementation Market is accounted to register a CAGR of 11.32% during the forecast period and is estimated to reach USD 5.512874091 Billion by 2032.

Viscosupplementation is a medical procedure used to alleviate joint pain and improve joint mobility, particularly in patients with osteoarthritis. It involves the injection of a gel-like substance, typically hyaluronic acid, directly into the affected joint. This gel acts as a lubricant and shock absorber, supplementing the natural synovial fluid present in the joint. By increasing the viscosity and reducing friction within the joint, viscosupplementation aims to reduce pain, inflammation, and stiffness, thereby improving joint function and overall quality of life for individuals suffering from osteoarthritis. 

The procedure is minimally invasive and can provide long-lasting relief, making it a valuable treatment option for managing the symptoms of osteoarthritis in various joints, such as the knees, hips, and shoulders.

Key Players

MRFR recognizes the following companies as the key players in the Global Viscosupplementation Market— Allergan, Sanofi, Hoffmann-La Roche, Smith & Nephew Plc, Zimmer Biomet, Anika Therapeutics Inc, Ferring B.V., Bioventus, and FidiaFarmaceutici S.P.A.

Segment Analysis

The Global Viscosupplementation Market has been segmented based on Hyaluronic Acid Type, and Distribution Channels.

Based on Hyaluronic Acid Type, the market is segmented into Stabilized Hyaluronic Acid, Standard Hyaluronic Acid. The Stabilized Hyaluronic Acid category dominates the Viscosupplementation market due to its superior stability, prolonged efficacy, and reliable performance in reducing joint pain and improving mobility in patients with osteoarthritis.

Based on Procedure Type, the market is segmented into Three-Injection Procedures. The Three-Injection Procedure category dominates the Viscosupplementation market due to its proven effectiveness, convenience, and widely accepted treatment protocol for providing sustained relief and improved joint function in patients with osteoarthritis.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Viscosupplementation Market Research Report

Regional Analysis

The Global Viscosupplementation Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global Viscosupplementation Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Global Viscosupplementation Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Global Viscosupplementation Market comprises of Middle East, Africa, and Latin America.

The dominance of the North American viscosupplementation market will be driven by the increasing preference for shorter treatment regimens, despite their higher cost, and the growing prevalence of target diseases like osteoarthritis in the region.

Europe holds the second-largest market share in viscosupplementation, primarily due to its rising geriatric population, while significant product innovation is expected to contribute to market growth. Germany leads the European market in terms of market share, and the UK experiences the fastest growth.

The Asia-Pacific viscosupplementation market is anticipated to grow at the fastest CAGR from 2023 to 2032, propelled by developing countries' initiatives to improve healthcare infrastructure, leading to increased regional trade. China holds the largest market share in the viscosupplementation market, and India demonstrates the fastest growth in the Asia-Pacific region.

Key Findings of the Study

• The Global Viscosupplementation Market is expected to reach USD 5.512874091 Billion by 2032, at a CAGR of 11.32% during the forecast period.


• The dominance of the North American viscosupplementation market is expected to be driven by the growing preference for shorter treatment regimens, despite higher costs, and the increasing prevalence of target diseases like osteoarthritis in the region.


• Based on the Hyaluronic Acid Type, the Market has been segmented into Stabilized Hyaluronic Acid holding the largest market in 2023.


• Allergan, Sanofi, Hoffmann-La Roche, Smith & Nephew Plc, Zimmer Biomet, Anika Therapeutics Inc, Ferring B.V., Bioventus, and FidiaFarmaceutici S.P.A.